Use of urinary globotriaosylceramide for fabry disease screening in Canada
Publication
, Journal Article
Auray-Blais, C; Cyr, D; Drouin, R; Clarke, JTR; Millington, DS
Published in: Clinical Therapeutics
November 19, 2008
Duke Scholars
Published In
Clinical Therapeutics
DOI
EISSN
1879-114X
ISSN
0149-2918
Publication Date
November 19, 2008
Volume
30
Issue
SUPPL. 3
Related Subject Headings
- Optoelectronics & Photonics
- 3214 Pharmacology and pharmaceutical sciences
- 3202 Clinical sciences
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Auray-Blais, C., Cyr, D., Drouin, R., Clarke, J. T. R., & Millington, D. S. (2008). Use of urinary globotriaosylceramide for fabry disease screening in Canada. Clinical Therapeutics, 30(SUPPL. 3). https://doi.org/10.1016/S0149-2918(08)00360-3
Auray-Blais, C., D. Cyr, R. Drouin, J. T. R. Clarke, and D. S. Millington. “Use of urinary globotriaosylceramide for fabry disease screening in Canada.” Clinical Therapeutics 30, no. SUPPL. 3 (November 19, 2008). https://doi.org/10.1016/S0149-2918(08)00360-3.
Auray-Blais C, Cyr D, Drouin R, Clarke JTR, Millington DS. Use of urinary globotriaosylceramide for fabry disease screening in Canada. Clinical Therapeutics. 2008 Nov 19;30(SUPPL. 3).
Auray-Blais, C., et al. “Use of urinary globotriaosylceramide for fabry disease screening in Canada.” Clinical Therapeutics, vol. 30, no. SUPPL. 3, Nov. 2008. Scopus, doi:10.1016/S0149-2918(08)00360-3.
Auray-Blais C, Cyr D, Drouin R, Clarke JTR, Millington DS. Use of urinary globotriaosylceramide for fabry disease screening in Canada. Clinical Therapeutics. 2008 Nov 19;30(SUPPL. 3).
Published In
Clinical Therapeutics
DOI
EISSN
1879-114X
ISSN
0149-2918
Publication Date
November 19, 2008
Volume
30
Issue
SUPPL. 3
Related Subject Headings
- Optoelectronics & Photonics
- 3214 Pharmacology and pharmaceutical sciences
- 3202 Clinical sciences
- 1115 Pharmacology and Pharmaceutical Sciences